Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of Blood, Blood Forming Organs and Immunologic DisordersDRG 815-reticuloendothelial-and-immunity-disorders-with-cc
    Ask Trek AI about this page

    Reticuloendothelial and Immunity Disorders with CC: Inpatient Reimbursement Overview

    DRG 815 encompasses admissions for reticuloendothelial and immunity disorders with a Complication or Comorbidity and covers conditions such as autoimmune disease exacerbations, immune deficiencies, and related hematologic inflammation that require inpatient care. Correct assignment matters for inpatient reimbursement because the Complication or Comorbidity designation increases case weight and thus affects Medicare payment for the hospital stay.

    Customize your policy alerts

    Sign up for drg 815 policy alerts

    Get alerted when payer policies referencing 815 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 815 Overview

    DRG 815 covers hospital admissions for primary reticuloendothelial and immunity system disorders with a documented Complication or Comorbidity. Typical clinical cases include autoimmune conditions, immunodeficiency states, and certain hematologic inflammatory disorders requiring inpatient diagnostic workup, immunomodulatory therapy, or management of infectious complications. This Diagnosis-Related Group is relevant for Medicare payment because the presence of a Complication or Comorbidity increases resource use and affects relative reimbursement weighting. Accurate coding of the principal diagnosis and accompanying complications influences payment assignment for inpatient stays.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute immunomodulatory intervention trials: Studies testing short-term therapies or treatment protocols aimed at rapidly controlling severe immune dysregulation, such as corticosteroid-sparing strategies, plasmapheresis timing, or biologic agent initiation in hospitalized patients with acute reticuloendothelial or immune-mediated complications. These trials enroll inpatients with pronounced cytopenias, hemophagocytic syndromes, severe autoimmune flare-ups, or organ-threatening immune cytotoxicity to define efficacy, safety, and optimal timing of interventions. Results are relevant to providers for clinical decision-making during high-acuity stays and to payers because inpatient treatment intensity and length of stay drive reimbursement under this DRG.
    • Comparative effectiveness and care-pathway studies: Research comparing different diagnostic and management pathways (for example, early comprehensive immunologic workup versus stepped testing, protocolized supportive care bundles versus usual care) for patients admitted with suspected reticuloendothelial disorders or complicated immune dysfunction. These trials or pragmatic studies focus on heterogeneous inpatient populations including patients with suspected hemolytic anemia, splenic disorders, immune thrombocytopenia, or unexplained fevers and cytopenias, measuring outcomes such as time to diagnosis, complications, resource utilization, and hospital length of stay. Findings inform clinicians on best practices and help payers and hospitals optimize resource allocation, reduce unnecessary testing or procedures, and standardize care that affects DRG payments.
    • Post-discharge outcomes and readmission prevention studies: Cohort studies and interventional trials aimed at reducing 30- and 90-day readmissions and long-term morbidity among patients discharged after an inpatient episode for reticuloendothelial or immune disorders. These investigations target transitional-care interventions, outpatient monitoring strategies (for cytopenias, immunosuppression complications), and risk stratification tools in populations with chronic or relapsing immune conditions that prompted hospitalization. Evidence from these studies is important to providers for planning follow-up and ongoing therapy choices and to payers because reduced readmissions and improved outpatient management can lower total cost of care associated with this DRG.

    Related Codes

    799-SPLENIC-PROCEDURES-WITH-MCC

    Splenic Procedures with MCC: Inpatient Reimbursement Overview

    800-SPLENIC-PROCEDURES-WITH-CC

    Splenic Procedures with CC: Inpatient Reimbursement Overview

    801-SPLENIC-PROCEDURES-WITHOUT-CC-MCC

    Splenic Procedures without CC/MCC: Inpatient Reimbursement Overview

    802-OTHER-O-R-PROCEDURES-OF-THE-BLOOD-AND-BLOOD-FORMING-ORGANS-WITH-MCC

    Other O.R. Procedures of the Blood and Blood Forming Organs with MCC: Inpatient Reimbursement Overview

    803-OTHER-O-R-PROCEDURES-OF-THE-BLOOD-AND-BLOOD-FORMING-ORGANS-WITH-CC

    Other O.R. Procedures of the Blood and Blood Forming Organs with CC: Inpatient Reimbursement Overview

    804-OTHER-O-R-PROCEDURES-OF-THE-BLOOD-AND-BLOOD-FORMING-ORGANS-WITHOUT-CC-MCC

    Other O.R. Procedures of the Blood and Blood Forming Organs without CC/MCC: Inpatient Reimbursement Overview

    808-MAJOR-HEMATOLOGICAL-AND-IMMUNOLOGICAL-DIAGNOSES-EXCEPT-SICKLE-CELL-CRISIS-AND-COAGULATION-DISORDERS-WITH-MCC

    Major Hematological and Immunological Diagnoses: Inpatient Reimbursement Overview

    809-MAJOR-HEMATOLOGICAL-AND-IMMUNOLOGICAL-DIAGNOSES-EXCEPT-SICKLE-CELL-CRISIS-AND-COAGULATION-DISORDERS-WITH-CC

    Major Hematological and Immunological Diagnoses: Inpatient Reimbursement Overview

    810-MAJOR-HEMATOLOGICAL-AND-IMMUNOLOGICAL-DIAGNOSES-EXCEPT-SICKLE-CELL-CRISIS-AND-COAGULATION-DISORDERS-WITHOUT-CC-MCC

    Major Hematological and Immunological Diagnoses: Inpatient Reimbursement Overview

    811-RED-BLOOD-CELL-DISORDERS-WITH-MCC

    Red Blood Cell Disorders with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 14

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.